A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Warfarin dosing is correlated with polymorphisms in vitamin K epoxide reductase complex 1 (VKORC1) and the cytochrome P450 2C9 (CYP2C9) genes. Recently, the FDA revised warfarin labeling to raise physician awareness about these genetic effects. Randomized clinical trials are underway to test genetically based dosing algorithms. It is thus important to determine whether common single nucleotide polymorphisms (SNPs) in other gene(s) have a large effect on warfarin dosing. A retrospective genome-wide association study was designed to identify polymorphisms that could explain a large fraction of the dose variance. White patients from an index warfarin population (n = 181) and 2 independent replication patient populations (n = 374) were studied. From the approximately 550 000 polymorphisms tested, the most significant independent effect was associated with VKORC1 polymorphisms (P = 6.2 x 10(-13)) in the index patients. CYP2C9 (rs1057910 CYP2C9*3) and rs4917639) was associated with dose at moderate significance levels (P approximately 10(-4)). Replication polymorphisms (355 SNPs) from the index study did not show any significant effects in the replication patient sets. We conclude that common SNPs with large effects on warfarin dose are unlikely to be discovered outside of the CYP2C9 and VKORC1 genes. Randomized clinical trials that account for these 2 genes should therefore produce results that are definitive and broadly applicable.

[1]  M. Rieder,et al.  Estimating coverage and power for genetic association studies using near-complete variation data , 2008, Nature Genetics.

[2]  Joshua M. Korn,et al.  Mapping and sequencing of structural variation from eight human genomes , 2008, Nature.

[3]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[4]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[5]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[6]  Brian F. Gage,et al.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues , 2008, Journal of Thrombosis and Thrombolysis.

[7]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[8]  M. Rieder.  Pharmacogenetics of warfarin treatment for potential clinical application , 2007 .

[9]  M. Rieder,et al.  γ‐Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose , 2007, Journal of thrombosis and haemostasis : JTH.

[10]  Pauline C Ng,et al.  Power to Detect Risk Alleles Using Genome-Wide Tag SNP Panels , 2007, PLoS genetics.

[11]  M. Stephens,et al.  Imputation-Based Analysis of Association Studies: Candidate Regions and Quantitative Traits , 2007, PLoS genetics.

[12]  Dana C Crawford,et al.  Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. , 2007, Pharmacogenomics.

[13]  Ingrid Glurich,et al.  Evaluation of Genetic Factors for Warfarin Dose Prediction , 2007, Clinical Medicine & Research.

[14]  D. Conrad,et al.  Global variation in copy number in the human genome , 2006, Nature.

[15]  B. Horne,et al.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study , 2006, Journal of Thrombosis and Thrombolysis.

[16]  P. Deloukas,et al.  Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.

[17]  Guoying Tai,et al.  The pharmocogenomics of warfarin: closing in on personalized medicine. , 2006, Molecular interventions.

[18]  Tom Schalekamp,et al.  VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation , 2006, Clinical pharmacology and therapeutics.

[19]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[20]  Dana C Crawford,et al.  The patterns of natural variation in human genes. , 2005, Annual review of genomics and human genetics.

[21]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[22]  M. Stephens,et al.  Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation , 2022 .

[23]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[24]  F. Martinez,et al.  Automated high-throughput sex-typing assay. , 2004, BioTechniques.

[25]  Sivakumar Gowrisankar,et al.  Pattern of sequence variation across 213 environmental response genes. , 2004, Genome research.

[26]  Samuel Z Goldhaber,et al.  Warfarin dosing and cytochrome P450 2C9 polymorphisms , 2004, Thrombosis and Haemostasis.

[27]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[28]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[29]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..

[30]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[31]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[32]  A. Rettie,et al.  A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin , 1999, Epilepsy Research.

[33]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.